Cipla today announced the launch of generic drug Sofosbuvir in India under the brand name 'Hepcvir'. Following the non-exclusive licensing agreement signed with Gilead Sciences in September last year, to manufacture and market chronic hepatitis C medicines, Cipla is now all set to make the drug Sofosbuvir available to Indian patients in a week's time.
Subhanu Saxena, managing director & Global chief executive officer, Cipla said, "Cipla has aways brought accessible and affordable medicines to fight against diseases like AIDS and Hepatitis B and is a leader in India with anti-virals; hence, Cipla had made it a priority to bring Hepcvir to patients in India as well as the other developing nations."
Shares of the company gained Rs 1.1, or 0.15%, to trade at Rs 711. The total volume of shares traded was 123,426 at the BSE (1.09 p.m., Wednesday).